Vincristine Sulfate
Generic Details
Generic Name
Vincristine Sulfate
Other Names
- Oncovin
- Vincasar PFS
Drug Class
- Vinca Alkaloid
Chemical Formula
C46H56N4O10S
Molecular Weight
824.04 g/mol
Mechanism of Action
- Inhibits microtubule formation in mitotic spindle, arresting cell division
Indications
- Acute lymphoblastic leukemia
- Hodgkin's disease
- Non-Hodgkin lymphomas
- Wilms tumor
- Neuroblastoma
- Rhabdomyosarcoma
- Multiple myeloma
Common Dosage Forms
- Injection
Typical Dosage
- 1.4 mg/m2 (maximum 2 mg) IV weekly for most indications
Pediatric Dosage
- 1.5-2 mg/m2 IV weekly for pediatric patients
Geriatric Dosage
- Dose adjustments may be needed based on individual patient factors
Side Effects
- Neurotoxicity
- Constipation
- Hair loss
- Peripheral neuropathy
- Bone marrow suppression
Contraindications
- Hypersensitivity to vincristine or any component of the formulation
- Charcot-Marie-Tooth disease
- In cases of impaired hepatic or renal function
Pregnancy Category
- D
Lactation Safety
- L3 - Considered moderately safe while breastfeeding
Drug Interactions
- CYP3A4 inducers/inhibitors
- Phenytoin
- St. John's Wort
- Digoxin
Overdose Symptoms
- Neurological toxicity
- Bone marrow suppression
- Gastrointestinal symptoms
Antidote for Overdose
- There is no specific antidote, management is supportive
Storage Conditions
- Store at 20-25°C (68-77°F), excursions permitted between 15-30°C (59-86°F)
Pharmacokinetics
- Absorption: Rapidly absorbed after IV administration
- Distribution: Highly protein-bound, widely distributed
- Metabolism: Primarily hepatic
- Excretion: Primarily via biliary excretion
Precautions
- Monitor for neurotoxicity
- Monitor blood counts regularly
- Avoid extravasation during IV administration
Warnings
- Severe neurotoxicity can occur, dose adjustments may be necessary based on toxicity levels
Others
- It is essential to administer vincristine sulfate under the supervision of a healthcare professional experienced in the use of chemotherapeutic medications.